

# 1 SARS-CoV-2 dynamics in New York City during March 2020–August 2023

2 Wan Yang,<sup>1\*</sup> Hilary Parton,<sup>2</sup> Wenhui Li,<sup>2</sup> Elizabeth A. Watts,<sup>2,3</sup> Ellen Lee,<sup>2</sup> Haokun Yuan<sup>1</sup>

3 <sup>1</sup>Department of Epidemiology, Columbia University, New York, NY, USA; <sup>2</sup>New York City  
4 Department of Health and Mental Hygiene, Queens, NY, USA; <sup>3</sup>Centers for Disease Control and  
5 Prevention, Atlanta, GA, USA

6 \*Correspondence to: wy2202@cumc.columbia.edu (WY)

## 7 8 Abstract

9 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been widespread since  
10 2020 and will likely continue to cause substantial recurring epidemics. However, understanding  
11 the underlying infection burden (i.e., including undetected asymptomatic/mild infections) and  
12 dynamics, particularly since late 2021 when the Omicron variant emerged, is challenging due to  
13 the potential for asymptomatic and repeat SARS-CoV-2 infection, changes in testing practices,  
14 and changes in disease reporting. Here, we leverage extensive surveillance data available in  
15 New York City (NYC) and a comprehensive model-inference system to reconstruct SARS-CoV-2  
16 dynamics therein from the pandemic onset in March 2020 to August 2023, and further validate  
17 the estimates using independent wastewater surveillance data. The validated model-inference  
18 estimates indicate a very high infection burden totaling twice the population size (>5 times  
19 documented case count) but decreasing infection-fatality risk (a >10-fold reduction) during the  
20 first 3.5 years. The detailed estimates also reveal highly complex variant dynamics and immune  
21 landscape, changing virus transmissibility, and higher infection risk during winter in NYC over  
22 this time period. These transmission dynamics and drivers, albeit based on data in NYC, may be  
23 relevant to other populations and inform future planning to help mitigate the public health  
24 burden of SARS-CoV-2.

## 25 26 INTRODUCTION

27 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019.  
28 Within months, it quickly spread worldwide, prompting the World Health Organization (WHO)  
29 to declare coronavirus disease 2019 (COVID-19) a global public health emergency on January  
30 30, 2020, a designation lasting for 3+ years through May 5, 2023 (1). Populations worldwide  
31 have experienced multiple COVID-19 pandemic waves, and will likely continue to endure  
32 recurring epidemics, even after the declared ending of the pandemic phase. Given the disease's  
33 historical importance, high potential to cause future epidemics, and long-term health impacts  
34 (e.g., long-COVID (2)), it is important to better understand its transmission dynamics, infection  
35 burden, and severity over time.

36  
37 Many studies have reported SARS-CoV-2 transmission dynamics during the initial and  
38 subsequent pandemic waves (3). However, transmission dynamics after the Omicron BA.1 wave

39 remain less characterized. Many Omicron subvariants have emerged after BA.1, causing  
40 outbreaks with varying magnitude and quickly supplanting one another (4). While surveillance  
41 systems (e.g., registries of laboratory-reported cases and death certificates) can provide  
42 invaluable information, potential biases (e.g., due to differential test-seeking behaviors) could  
43 limit the understanding of epidemic dynamics (5-7). For example, underlying SARS-CoV-2  
44 infection rates were not completely captured by surveillance based on clinical testing due to  
45 high rates of asymptomatic and mild infection (8, 9) and use of at-home testing, the results of  
46 which are not reported to health departments (10), nor were they captured by serologic  
47 surveys due to high rates of reinfection. Due to these limitations, to what extent populations  
48 are (re)infected by each subvariant and what drives the Omicron-subvariant waves – e.g.,  
49 increased transmissibility and/or immune evasion – remain unclear.

50  
51 In this study, we leverage extensive surveillance data available in New York City (NYC) and a  
52 comprehensive model-inference system to reconstruct the underlying SARS-CoV-2 transmission  
53 dynamics therein during March 2020 – August 2023. NYC is a densely populated, large, urban  
54 center with 8+ million people that became one of the first pandemic epicenters in March 2020.  
55 We have previously reported model-inference estimates for the first two pandemic waves (11-  
56 13). Here, we fit a more detailed model to age- and neighborhood-specific data of COVID-19  
57 cases, emergency department (ED) visits, and deaths, and validate model-inference estimates  
58 using independent SARS-CoV-2 wastewater viral load data, i.e., measurements of population-  
59 level SARS-CoV-2 fecal shedding that are less subject to testing biases. The validated model-  
60 inference estimates allow quantification of weekly infection rates by each (sub)variant and key  
61 epidemiologic features including the underlying population susceptibility, variant-specific  
62 transmissibility, and infection-fatality risk (IFR) over time since the pandemic onset. Overall, we  
63 estimate a very high infection burden totaling twice the population size (>5 times the case  
64 count) but decreasing IFRs (a >10-fold reduction across all age groups), and highlight several  
65 key factors driving transmission dynamics, during the initial 3.5 years of SARS-CoV-2 circulation.

66  
67 RESULTS

68 **The model-inference system reconstructed underlying SARS-CoV-2 infection dynamics that**  
69 **are consistent with independent SARS-CoV-2 wastewater surveillance data.**

70 The model-inference system is able to recreate the epidemic curves of weekly cases, ED visits,  
71 and deaths, combining all ages (Fig 1A) and for individual age groups (Fig S1). Given the large  
72 uncertainty due to changes in clinical testing and reporting requirements, we further validate  
73 the estimates using independent SARS-CoV-2 wastewater surveillance data not used for model  
74 inference. As shown in Fig 1B, the estimated number of infectious people per 100,000  
75 population per week closely tracked the measured SARS-CoV-2 load in wastewater. This close  
76 agreement is evident for all three major periods, i.e., the 2<sup>nd</sup> wave mostly due to the ancestral

77 and Iota variants during Fall 2020/Winter 2021 (Fig 1B, 1<sup>st</sup> panel; Pearson correlation coefficient  
78  $r = 0.91$ , 95% confidence interval [CI]: 0.84-0.95), the Delta wave during Summer/Fall 2021 (Fig  
79 1B, 2<sup>nd</sup> panel;  $r = 0.64$ , 95% CI: 0.29-0.84), and the Omicron period since late November 2021  
80 (Fig 1B, 3<sup>rd</sup> panel and inset for recent months;  $r = 0.89$ , 95% CI: 0.84-0.93). These results  
81 indicate the model-inference system adequately accounted for changing infection-detection  
82 rates over time, and accurately reconstructed the underlying SARS-CoV-2 infection rates and  
83 transmission dynamics during the study period.

84

### 85 **Overview of the COVID-19 pandemic/epidemic dynamics through August 2023**

86 During the study period (the week starting March 1, 2020, to the week starting August 27,  
87 2023), 3.2 million confirmed and probable cases were reported to the NYC Department of  
88 Health and Mental Hygiene (NYC Health Department) (or 38.2% of the size of the city's  
89 population; Table 1). However, estimated infections totaled 17.4 million [95% credible interval  
90 (CrI): 14.2-21.5], more than five times the documented case count. During the pre-Omicron  
91 period (March 2020 – November 2021), the model-inference system estimated cumulative  
92 infections totaling 53.7% (95% CrI: 43.7-64.6%) of the size of the city's population; these  
93 estimates include all infections, and do not distinguish between initial and subsequent  
94 infections for the same individual. Most of these infections were caused by the ancestral and  
95 Iota variants during the 1<sup>st</sup> and 2<sup>nd</sup> waves (estimated 38.0% of the size of the city's population,  
96 95% CrI: 19.7-75.4%), followed by Delta (8.4%, 95% CrI: 4.9-21.3%) and Alpha (2.9%, 95% CrI:  
97 1.5-5.6%).

98

99 During the Omicron period (November 2021 – August 2023), (re)infections by the Omicron  
100 subvariants alone tripled, totaling 12.9 million (95% CrI: 10.5-16.1), or 153.3% (95% CrI: 124.8-  
101 192.0%) of the size of the city's population. The BA.1 wave was the largest Omicron-subvariant  
102 wave thus far, infecting around 40% of the size of the city's population, or 3.5 million people  
103 (95% CrI: 2.2-5.6), within roughly two months (Table 1 and Fig 2A). After BA.1 subsided,  
104 multiple Omicron subvariants circulated in NYC. By the end of August 2023, at least 14 Omicron  
105 subvariants including BA.1 had an estimated cumulative infection rate surpassing 1% of the  
106 city's population size (vs. only four such variants prior to Omicron; Table 1). Multiple smaller  
107 Omicron-subvariant waves occurred, often with several subvariants cocirculating (Fig 2A). Most  
108 notably, the BA.2/BA.2.12.1 wave occurred during Spring/Summer 2022, the BA.5 wave during  
109 Summer/Fall 2022, and the XBB.1.5 wave during Winter 2023, each infecting around 20% of the  
110 size of the city's population (Table 1 and Fig 2A).

111

### 112 **Key factors driving SARS-CoV-2 transmission dynamics.**

113 SARS-CoV-2 transmission dynamics have been driven by multiple factors, including use of  
114 nonpharmaceutical interventions (NPIs), population immunity (due to prior infection and/or

115 vaccination), new variants, and seasonal risk of infection (11-13), all of which were accounted  
116 by the model-inference system (see Methods). Since NPIs have become less prevalent during  
117 more recent waves (e.g., mask mandate in NYC schools was lifted in March 2022 (14)), here we  
118 focus on reporting the impact of the other aforementioned factors.

119  
120 First, population susceptibility varies following surges in infections, vaccinations, and  
121 circulations of immune evasive variants (Fig 2B), and in turn determines the epidemic  
122 trajectory. Before the Delta wave, mixed immunity from both prior infections and vaccinations  
123 collectively lowered population susceptibility such that the sums (stacked bars, from top to  
124 bottom, in Fig 2B; see details in Methods) closely tracked the complement of estimated  
125 susceptibility (i.e., the estimated composite population immunity against infection; see blue  
126 line and shaded area in Fig 2B). The Delta variant partially evaded both infection- and vaccine-  
127 induced immunity (15, 16) such that the estimated susceptibility substantially increased during  
128 the Delta wave; the estimated population immunity was lower than the sum of prior infections  
129 and vaccinations (note this sum would roughly reflect the maximum of expected population  
130 immunity, should there be no immune evasion; see the stacked bars dipping below the blue  
131 line in Fig 2B). Nonetheless, strong mixed immunity at the time (>50%; see stacked bars and  
132 blue lines in Fig 2B) likely helped to temper the intensity of the Delta wave in Summer 2021.

133  
134 Omicron BA.1 was highly immune evasive against all pre-existing variants (17-19). After  
135 adjusting for the lower vaccine effectiveness and weaker immunity from pre-Omicron  
136 infections (see Methods), the combined mixed immunity (stacked bars) closely matched the  
137 complement of estimated susceptibility (blue line) during the BA.1 wave (Fig 2B). It is evident  
138 from Fig 2B that rapid accumulation of BA.1 infection (pink bars) along with fast uptake of the  
139 3<sup>rd</sup> vaccine dose (open bars) at the time substantially increased population immunity, which  
140 likely accelerated the decline of BA.1. The large BA.1-infection-induced immunity also appeared  
141 to curb immediate surge of subsequent Omicron subvariants – particularly, BA.2/BA.2.12.1 and  
142 BA.5, even though these subvariants were able to partially evade that prior immunity (20, 21)  
143 (Fig 2B, see the stacked bars dipping below the blue line during Summer 2022). However, in Fall  
144 2022/Winter 2023, infection-induced immunity appeared to come from a large number of post-  
145 BA.1 subvariants, accumulated through their continued spread (see increasing number of  
146 colors, each representing one subvariant, during the last part of the study period in Fig 2 A and  
147 B).

148  
149 Second, virus transmissibility ( $R_{TX}$ ) can increase, helping newer variants to outcompete pre-  
150 existing ones. Here, to capture virus-specific transmissibility (17, 22), we separated the effects  
151 of changing population susceptibility, NPIs, and seasonal risk of infection. Unlike the effective  
152 reproduction number  $R_t$  (i.e., the average number of secondary infections (23)), which can

153 fluctuate due to the aforementioned effects, changes in  $R_{TX}$  closely followed the surge of major  
154 variants (see large drops in  $R_t$  around the pandemic onset due to NPIs in Fig S2A vs. the relative  
155 stable  $R_{TX}$  in Fig 2C). That is, here  $R_{TX}$  is akin to the basic reproduction number  $R_0$  (i.e., the  
156 average number of secondary infections *in a naïve population* (23)) that measures the inherent  
157 transmissibility of a virus, and can be tracked over time for, e.g., new variants (vs.  $R_0$  being  
158 estimated only at the pandemic onset when the entire population is susceptible; see Methods  
159 and refs (17, 22)).

160  
161 In the above context, we estimate that virus transmissibility ( $R_{TX}$ ) has increased by nearly 3-fold  
162 in three years, but has appeared to level off since the latter half of 2022 (Fig 2C). Consistent  
163 with previous estimates (13, 24), Iota and Alpha increased virus transmissibility, allowing them  
164 to outcompete the ancestral variant during the 2<sup>nd</sup> wave. In NYC,  $R_{TX}$  increased by ~20% during  
165 the 2<sup>nd</sup> wave largely due to the mixed circulation of Iota and Alpha (Table 2). The Delta variant  
166 further increased virus transmissibility by another ~30% (or ~60% compared to the ancestral  
167 variant; Table 2), which, along with its immune evasive ability, allowed it to spread during  
168 Summer and Fall 2021 despite the relatively high population immunity at the time (Fig 2B). The  
169 Omicron BA.1 subvariant further increased virus transmissibility. In NYC, average  $R_{TX}$  during the  
170 BA.1 wave was 2.3 times the 1st (ancestral variant) wave and further increased by ~20% post-  
171 BA.1. Importantly,  $R_{TX}$  remained around the same level through August 2023 (Table 2 and Fig  
172 2C), suggesting immune evasion and waning immunity (Fig S2D) have been stronger drivers of  
173 the subvariant turnover since Summer 2022.

174  
175 Third, seasonal conditions such as humidity and temperature may modulate the transmission of  
176 respiratory viruses including SARS-CoV-2 (25-28); in particular, low humidity and low  
177 temperature conditions commonly seen during the winter are conducive for SARS-CoV-2  
178 survival (25). In addition, indoor crowding with reduced ventilation may also facilitate  
179 transmission (29). While infection rates could surge during summer months when new variants  
180 emerge, higher infection rates have occurred during winter months, peaking in December or  
181 January in NYC during the 3.5-year study period (Fig 3A). This pattern is further evident from Fig  
182 3B, where the scaled infection rates during winter months were often more than twice as high  
183 as the summer months. This timing, despite multiple concurrent drivers including new variant  
184 emergence, highlights higher SARS-CoV-2 infection risk during the winter months in NYC during  
185 this study period.

### 186 187 **Changes in infection-detection rate**

188 The infection-detection rate (i.e., case ascertainment rate) represents the proportion of  
189 infections detected as cases, and is crucial for accurate estimation of specific outcomes (e.g.,  
190 infection rates and infection-fatality risk) to inform public health response (30). Estimating the

191 infection-detection rate of SARS-CoV-2 has been challenging due to multiple factors (e.g.,  
192 undetected asymptomatic/mild infections) (5, 6, 30). Here we resolved these challenges by  
193 comprehensive model inference (see Methods) and validated estimated infection-detection  
194 rates in NYC using independent wastewater surveillance data (Fig 1). In NYC, estimated  
195 infection-detection rates were very low at the onset of the 1<sup>st</sup> pandemic wave and the Omicron  
196 BA.1 wave – only 2.1% (95% CrI: 0.2-4.5%) and 3.0% (95% CrI: 1.1-5.4%) of infections were  
197 detected as cases, respectively (Fig 3C). Estimated infection-detection rate increased  
198 substantially after the initial weeks of the pandemic but fluctuated over time (Fig 3C); the  
199 highest rates were estimated during the week of January 3, 2021 (42.7%, 95% CrI: 27.9-56.2%)  
200 before the Omicron variant emerged, and during the week of December 12, 2021 following the  
201 emergence of Omicron BA.1 (45.7%, 95% CrI: 28.4-67.2%). However, estimated infection-  
202 detection rate decreased steadily over time after Spring 2022 and was just ~5% since Summer  
203 2023 (Fig 3C), which is comparable to the initial weeks of the pandemic.

204

### 205 **Changes in infection-fatality risk (IFR)**

206 IFR is a key indicator of COVID-19 severity. As reported previously, IFR of SARS-CoV-2 increased  
207 log-linearly with age (31, 32), particularly before mass-vaccination. Thus, we estimated IFR by  
208 age group (see Fig 4, Table 2 and Table S1). Consistent with previous reports (12, 13, 33, 34),  
209 estimated IFR in NYC was highest during the 1<sup>st</sup> wave (March – May 2020). By the 2<sup>nd</sup> wave  
210 (roughly October 2020 – May 2021), IFR had declined by more than half for most age groups,  
211 even though it increased transiently due to circulation of variants such as Iota and Alpha (Fig 4  
212 D and E for those older than 65 years; and Table S2). During the latter half of 2021, IFR  
213 continued to decline, which likely was influenced by greater population immunity (Fig 2B).  
214 Another substantial decline in IFR occurred following the circulation of Omicron BA.1, which  
215 was milder than pre-existing variants as reported previously (35). In NYC, estimated IFR during  
216 the Omicron BA.1 wave (December 2021- February 2022) declined by around half compared to  
217 the Delta wave (July – November 2021), for most age groups (Fig 4 and Table S1). After the  
218 Omicron BA.1 wave, overall IFR continued to decline, mostly driven by the lowering IFR among  
219 those aged 75 or older (Fig 4 E and F; Table 2 and Table S1). Starting the week of April 23, 2023,  
220 COVID-19 deaths were classified in NYC per a revised definition (see Methods). To examine the  
221 potential impact due to this change, we have also computed IFR including only weeks before  
222 the April 23, 2023 revision. The stratified IFR estimates were similar to those through the week  
223 of August 27, 2023 (Table S1).

224

### 225 **DISCUSSION**

226 Using comprehensive model inference and data, we have reconstructed the transmission  
227 dynamics of SARS-CoV-2 in NYC during March 2020 – August 2023. The detailed model-  
228 inference estimates, further validated using independent SARS-CoV-2 wastewater surveillance

229 data (Fig 1), can be used to inform future planning in the city (e.g., to gauge future SARS-CoV-2  
230 infection burden and related health care needs). In addition, these estimates help to reveal the  
231 highly complex infection dynamics of SARS-CoV-2 and illustrate the key drivers in its continued  
232 spread, which may be shared by other populations. Below we focus on highlighting the general  
233 SARS-CoV-2 dynamics and key driving mechanisms.

234  
235 By the end of August 2023, the estimated infection rate totaled twice the population size,  
236 indicating the majority of NYC residents may have had at least 2 (re)infections during the first  
237 3.5 years. In addition, 81% of the population received the primary COVID-19 vaccine series, 40%  
238 have had an additional monovalent dose, and 23% have had either two additional monovalent  
239 doses or a bivalent vaccine (NYC vaccination data; as of 8/31/2023). In combination, these  
240 estimates and data suggest a high mixed population immunity. The high mixed population  
241 immunity would likely help mitigate the severity of future epidemics. Estimated IFR dropped by  
242 more than 10-fold for most age groups by August 2023, potentially attributable to multiple  
243 factors, including accumulated mixed immunity, access to improved treatment, and circulation  
244 of the milder Omicron subvariants. The potential long-term population health impact of this  
245 high infection rate is uncertain given the possibility of post-acute sequelae of SARS-CoV-2  
246 infection (i.e., long-COVID (2, 36)).

247  
248 As noted previously (3), the ability of SARS-CoV-2 to sustain continued spread in an already  
249 highly infected/vaccinated population has largely come from new variants, which can evade  
250 prior immunity and/or increase transmissibility. However, the dynamics and relative  
251 importance of these drivers have changed over time. Here, our estimates for NYC help to  
252 inform the interaction of these drivers during the first 3.5 years. When the underlying infection  
253 rate was relatively low (e.g., the first two waves), our estimates showed increased virus  
254 transmissibility predominantly drove SARS-CoV-2 variant dynamics (e.g., Alpha outcompeting  
255 pre-existing variants). As infections and immunity accumulated, we found stronger immune  
256 evasion allowed new variants to outcompete pre-existing and co-circulating subvariants,  
257 though transmissibility could also increase (Delta and BA.1 are both exemplars). By mid-2022,  
258 virus transmissibility appeared to stabilize after a nearly 3-fold increase (Fig 2C). Meanwhile,  
259 immune evasion continued but appeared to occur across multiple subvariants, each with a  
260 smaller subset of mutations, which may have allowed them to co-circulate and traverse pockets  
261 of resusceptible subpopulations (Fig 2B, see small changes in susceptibility after the Omicron  
262 BA.1 wave, despite substantial infections by 10+ Omicron subvariants). Whether this is a typical  
263 pathway of viral evolution to endemicity or whether another major Omicron BA.1-like new  
264 variant would emerge due to the nearly saturated immune landscape remains unknown.

265

266 The decrease in COVID-19 testing and data collection since early 2022 has raised concerns of  
267 timely situational awareness including new variant detection (37-39). Since late 2022/early  
268 2023, the United States national surveillance strategy (40, 41) has further shifted to mainly  
269 monitoring infection trends and severity (e.g., hospitalizations and mortality), along with  
270 genomic surveillance and wastewater surveillance. Here, we estimated very low initial  
271 infection-detection rates – roughly, only 1 in 50 infections were detected – at the onset of the  
272 first pandemic wave and Omicron BA.1 wave in NYC. In addition, we found that population  
273 mobility (an indicator of community mitigation via social distancing (11, 42-44)) was inversely  
274 correlated with infection-detection rates during the initial weeks – that is, the lack of  
275 community mitigation coincided with low infection-detection rates at the time (see preliminary  
276 analysis in Table S2). The low infection-detection rates may have facilitated unchecked silent  
277 spread of SARS-CoV-2 during those initial weeks, as it likely did in other places (45). While the  
278 infection-detection rate increased by more than 10-fold during the pandemic, it has again  
279 declined to a very low level (Fig 3C). A fuller appreciation of under-detection in the design and  
280 implementation of surveillance systems is thus needed, as are innovative approaches to  
281 increase detection and awareness (e.g., wastewater surveillance with timely data sharing (46)).

282  
283 Lastly, we note several study limitations. First, we did not account for population migration,  
284 which could lead to overestimation of the increase in susceptibility. In particular, the increase in  
285 population susceptibility after the Omicron BA.1 wave could be in part due to incoming  
286 population with a higher susceptibility than local residents (as NYC likely had a larger Omicron  
287 BA.1 wave and higher vaccination coverage than elsewhere), rather than entirely due to  
288 immune evasion of subsequent Omicron subvariants. Second, due to the discontinuation of  
289 SafeGraph mobility data (47), for weeks in 2023, we used mobility trends constructed based on  
290 historical data during the pandemic years 2020-2022 (vs. real-time mobility data for weeks  
291 before 2023; see Methods) to account for the impact of NPIs. However, we do not expect this  
292 to substantially affect the model-inference estimates, as the historical mobility trend was  
293 consistent with real-time subway ridership data (Fig S3). Third, the variant proportions among  
294 sequenced samples were used to estimate the variant-specific infection rates. However, as  
295 these samples may not be representative of the NYC population, estimates may reflect biases in  
296 the populations for which SARS-CoV-2 testing and sequencing were conducted. Lastly, per  
297 recommendation of the Council of State and Territorial Epidemiologists (CSTE), COVID-19-  
298 associated deaths were classified using a revised definition based solely on cause of death listed  
299 on the death certificate, for weeks from April 23, 2023 onwards. This revised definition could  
300 lead to missing COVID-19-associated deaths and thus underestimation of IFR afterwards.  
301 Nonetheless, a similar decline in IFR was estimated in the stratified analysis excluding weeks  
302 after the revision (Table S1), indicating a true continued decline in IFR after the Omicron BA.1  
303 wave.



304  
305 In summary, using comprehensive epidemiological data and model inference, we have  
306 described potential transmission dynamics of SARS-CoV-2 during its first 3.5 years of circulation  
307 in NYC, a large, urban center. Study findings highlight immune evasion, transmissibility  
308 increases, and higher infection risk during winter as key transmission drivers during the study  
309 period; these may be observed in other populations and could inform future planning to help  
310 mitigate the public health burden of SARS-CoV-2.

311  
312 **METHODS**

313 **Data sources and processing.**

314 For the model-inference system, we utilized multiple sources of epidemiologic data, including  
315 confirmed and probable COVID-19 cases, ED visits, deaths, vaccination, and variant proportions.  
316 As done and described previously (11-13), we aggregated all COVID-19 confirmed and probable  
317 cases (48, 49), COVID-19-associated ED visits (13, 50), and COVID-19-associated deaths (49)  
318 reported to the NYC Health Department by age group (<1, 1-4, 5-14, 15-24, 25-44, 45-64, 65-74,  
319 and 75+ year-olds), neighborhood of residence (42 United Hospital Fund neighborhoods in NYC  
320 (51)), and week of occurrence (13). For mortality, we note a change in COVID-19-associated  
321 death definitions. From March 1, 2020 – April 2, 2023, COVID-19-associated deaths included 1)  
322 deaths occurring in persons with laboratory-confirmed SARS-CoV-2 infection (i.e., confirmed  
323 COVID-19-associated death) at any point (March 1, 2020 – July 23, 2020), within 60 days (July  
324 24, 2020 – August 2, 2021), or within 30 days (August 3, 2021 – April 2, 2023) of diagnosis; and  
325 2) deaths with COVID-19, SARS-CoV-2 or a similar term listed on the death certificate as an  
326 immediate, underlying, or contributing cause of death but without laboratory-confirmation of  
327 COVID-19 (i.e., probable COVID-19-associated death) (52). From April 3, 2023 through the week  
328 of August 27, 2023 (i.e., end of this study), COVID-19-associated deaths included any death  
329 where the death certificate included COVID-19 or a common variation of COVID-19, SARS-CoV-  
330 2, coronavirus, etc. (53). For vaccinations, we included all available vaccine doses to date (i.e.,  
331 1<sup>st</sup> to 5<sup>th</sup> dose), and aggregated data for each vaccine dose to the same age/neighborhood  
332 strata, by date of vaccination (54).

333  
334 To model the impact of NPIs, as done previously (11-13), we used mobility data from SafeGraph  
335 (47) to adjust SARS-CoV-2 transmission rate. Note, however, the model-inference system also  
336 included a parameter to capture the overall impacts of NPIs not limited to mobility reduction  
337 (e.g., additional interventions such as masking; see below). The SafeGraph data were  
338 aggregated to the neighborhood level by week without age stratification, and available from  
339 the week of March 1, 2020 to the week of December 19, 2022. For the week of December 26,  
340 2022 to the week of August 27, 2023 (i.e., end of our study period), a comparison of historical  
341 SafeGraph data (i.e., weeks during March 2020 – December 2022, using the maximum mobility

342 recorded for the corresponding week of year to account for seasonal changes) showed a close  
343 agreement with real-time subway ridership data (Fig S3). Thus, we used historical SafeGraph  
344 data for those weeks.

345  
346 To compute the variant-specific estimates, we used reported weekly percentage of individual  
347 variants among sequenced samples (55, 56). Variant proportion data started from the week of  
348 December 27, 2020, and likely did not fully capture the share of Iota, a major variant that  
349 emerged around Fall 2020. Therefore, we combined the ancestral and Iota variants when  
350 computing the total number of cases or infections attributable to these variants.

351  
352 For model validation, we used SARS-CoV-2 wastewater surveillance data, available from August  
353 31, 2020 onward. Specifically, SARS-CoV-2 RNA concentrations were measured at each of the  
354 city's 14 wastewater treatment plants, often twice per week, using quantitative reverse  
355 transcription polymerase chain reaction (RT-qPCR) assays during August 31, 2020 – April 11,  
356 2023 and reverse transcription digital PCR (RT-dPCR) assays from November 1, 2022 through  
357 the week of August 27, 2023 (i.e., end of this study). For weeks after April 11, 2023 when the  
358 samples were measured using RT-dPCR alone, we converted the RT-dPCR measurements to RT-  
359 qPCR equivalents, by multiplying a simple conversion ratio (i.e., the mean of all RT-qPCR  
360 measurements dividing the mean of all RT-dPCR measurements during November 1, 2022 –  
361 April 11, 2023 when both assays were conducted). To compute the citywide weekly per-capita  
362 SARS-CoV-2 wastewater concentrations, we first averaged the per-capita SARS-CoV-2  
363 concentrations (i.e., normalized by sewershed flow rate and population size) for each week and  
364 sewershed, and then further aggregated the sewershed-level measurements to the city level  
365 (i.e., weighted mean per the population size).

366  
367 This activity was classified as public health surveillance and exempt from ethical review and  
368 informed consent by the Institutional Review Boards of both Columbia University and NYC  
369 Health Department.

### 370 371 **Model inference to estimate key epidemiological variables and parameters**

372 We used a model-inference system to estimate epidemiological variables and parameters  
373 based on case, ED visit, and mortality data, accounting for NPIs, vaccinations, under-detection  
374 of infection, and seasonal changes. Built on an approach described in Yang et al. (13), here the  
375 model-inference system additionally tracks the number of vaccinated individuals and accounts  
376 for all vaccine doses as done in ref (57). Briefly, the model-inference system uses a  
377 metapopulation network SEIRSV (Susceptible-Exposed-Infectious-(re)Susceptible-Vaccination)  
378 model (Eq. 1) to simulate the transmission of SARS-CoV-2 by age group and neighborhood:

379

$$\left\{ \begin{aligned} \frac{dS_i}{dt} &= \frac{R_i}{L} - \left( S_i \sum_{j=1}^{j=42} \frac{b_s b_j \beta_{city} m_{ij} I_j}{N_j} \right) + \sum_{\tau=0}^{\tau=T} \rho_{\tau} V_{i,t-\tau} - \sum_{k=1}^{k=K} v_{i,k} \\ \frac{dE_i}{dt} &= \left( S_i \sum_{j=1}^{j=42} \frac{b_s b_j \beta_{city} m_{ij} I_j}{N_j} \right) - \frac{E_i}{Z} \\ \frac{dI_i}{dt} &= \frac{E_i}{Z} - \frac{I_i}{D} \\ \frac{dR_i}{dt} &= \frac{I_i}{D} - \frac{R_i}{L} \\ \frac{dV_i}{dt} &= \sum_{k=1}^{k=K} v_{i,k} - \sum_{\tau=0}^{\tau=T} \rho_{\tau} V_{i,t-\tau} \end{aligned} \right. \quad [1]$$

380

381 where  $S_i$ ,  $E_i$ ,  $I_i$ ,  $R_i$ ,  $V_i$ , and  $N_i$  are the number of susceptible, exposed (but not yet infectious),  
 382 infectious, recovered and immune (i.e., protected against infection), vaccinated and immune  
 383 individuals, and the total population (58), respectively, from a given age group (i.e., <1, 1-4, 5-  
 384 14, 15-24, 25-44, 45-64, 65-74, or 75+ years) in neighborhood- $i$  ( $i = 1, \dots, 42$ , for the 42  
 385 neighborhoods in the city).  $\beta_{city}$  is the average citywide transmission rate;  $b_s$  is the estimated  
 386 seasonal trend (12). The term  $b_i$  represents the neighborhood-level transmission rate relative to  
 387 the city average. The term  $m_{ij}$  represents the changes in contact rate in each neighborhood (for  
 388  $i=j$ ) or spatial transmission from neighborhood- $j$  to  $i$  (for  $i \neq j$ ) and was computed based on the  
 389 mobility data (12). Here, we did not explicitly model the impact of individual NPI such as  
 390 masking, due to the lack of data and the minor impact of masking at the population level  
 391 (estimated 5-20% reduction (11, 42, 59)). Rather, to account for the overall impact of NPIs  
 392 including masking, we scaled the mobility data by a multiplicative factor to capture the overall  
 393 NPI effectiveness when computing  $m_{ij}$  (12).  $Z$ ,  $D$ , and  $L$  are the latency period, infectious period,  
 394 and immunity period, respectively. Note that as all state variables and parameters are time  
 395 varying and for each age group separately, Eq. 1 omits time ( $t$ ) and age in the subscripts.

396

397 To account for vaccination,  $v_{i,k}$  is the number of neighborhood- $i$  residents who were  
 398 immunized after the  $k$ -th dose ( $k = 1, 2, \dots, 5$  here for up to 5 doses of vaccines to date) at the  
 399 time step ( $t$ ), and was computed using vaccination data adjusting for vaccine effectiveness (VE)  
 400 against infection (60-64). Thus, the term  $\sum_{k=1}^{k=K} v_{i,k}$  represents the total number of  
 401 neighborhood- $i$  residents immunized by any dose of vaccine at the time step. The term  
 402  $\sum_{\tau=0}^{\tau=T} \rho_{\tau} V_{i,t-\tau}$  accounts for the waning of vaccine protection against infection, where  $V_{i,t-\tau}$  is the  
 403 number of neighborhood- $i$  residents who got vaccinated  $\tau$  days ago and lost protection on day-  
 404  $t$ , and  $\rho_{\tau}$  is the VE waning probability computed based on VE duration data (63). Note, here we  
 405 focused on modeling the impact of vaccination on population susceptibility, and that the  
 406 posterior estimates of population susceptibility were made along with other factors (e.g.,  
 407 infection) using several data streams and model inference as described below.

408

409 Using the model-simulated number of infections occurring each day, we further computed the  
410 number of cases, ED visits, and deaths each week to match with the observations, as described  
411 in (12, 13). Using cases as an example, we multiplied the model-simulated number of new  
412 infections per day by the infection-detection rate (i.e., case ascertainment rate, or the fraction  
413 of infections reported as cases), and further distributed these estimates in time per a  
414 distribution of time-from-infection-to-case-detection (Table S3); we then aggregated the daily  
415 lagged, simulated estimates to weekly totals for model inference.

416

417 Each week, the system uses the ensemble adjustment Kalman filter (EAKF) (65) to compute the  
418 posterior estimates of model state variables and parameters based on the model (prior)  
419 estimates and observed case, ED visit, and mortality data per Bayes' rule (12, 13). In particular,  
420 model posterior estimates include 1) the underlying infection rate including those not reported  
421 as cases, for each week (Fig 2A and C); 2) the number of susceptible individuals (i.e.,  $S_i$ ), which  
422 provides estimates of population susceptibility over time (Fig 2B); 3) the citywide transmission  
423 rate ( $\beta_{city}$ ) and infectious period (see estimates in Fig S2 B and C), which we multiplicatively  
424 combined to compute the time-varying virus transmissibility ( $R_{TX}$ , as measure of variant-specific  
425 infectiousness as described in (17, 22); Fig 2C); and 4) other key parameters such as the  
426 infection-detection rate (Fig 3C), IFR (Fig 4), and the real-time production number ( $R_t$ ; see  
427 estimates in Fig S2A).

428

429 We ran the model-inference system for the pre-Omicron and Omicron periods, separately. For  
430 the pre-Omicron period, we initiated the system at the week of March 1, 2020 (i.e., the week  
431 the first cases were detected in NYC), and ran it continuously through the week of December 5,  
432 2021 (i.e., the week before the Omicron BA.1 variant was detected in >50% of sequenced  
433 cases). For the Omicron period, we reinitiated the system at the week of November 21, 2021  
434 and ran it continuously through the end of the study period; given the initial overlap with the  
435 Delta variant in November/December 2021, we computed the number of cases, ED visits, and  
436 deaths due to Omicron based on the variant proportion data and used those variant-specific  
437 estimates for inference. To account for model uncertainty, we ran the model-inference system  
438 10 times, each with 500 ensemble members randomly drawn from the initial prior ranges  
439 (Table S3), and combined the posteriors from all runs, as done in (12).

440

#### 441 **Model validation using SARS-CoV-2 wastewater surveillance data**

442 To validate model-inference estimates, we compared the infection prevalence estimates (i.e.,  
443 the estimated number of infectious individuals, including those not detected as cases, in the  
444 population each week) to independent SARS-CoV-2 wastewater concentration data (i.e., the  
445 collective SARS-CoV-2 viral shedding of the population, regardless of clinical testing practices).

446 While both quantities represent the presence of SARS-CoV-2 in the population, the  
447 measurements are on different scales and viral shedding per infection could vary by the  
448 infecting variant. Thus, for comparison, we separated the data into three periods: i) August 31,  
449 2020 (i.e., the first day of wastewater surveillance) – June 26, 2021, predominantly the  
450 ancestral and Iota variants; ii) June 27, 2021 (i.e., the first week the share of Delta exceeding  
451 50% among the sequenced samples) – November 20, 2021, predominantly the Delta variant;  
452 and iii) November 21, 2021 (i.e., the first week Omicron BA.1 was detected) – August 29, 2023  
453 (i.e., the last wastewater sample during the study period), predominantly the Omicron  
454 subvariants. We scaled the wastewater measurements by multiplying the ratio of mean  
455 infection prevalence estimates and mean wastewater concentrations across all weeks of each  
456 period, and overlay the two time series for visual inspection (see Fig 1B).

457

#### 458 **Estimating variant-specific infection rates**

459 The weekly infection rate estimates from the model-inference system are based on surveillance  
460 data combining all reported variants and thus represent infections by any variant circulating  
461 during the week. To estimate the variant-specific infection rates for each week, we multiplied  
462 the overall infection rate estimate by the proportion among the sequenced samples for each  
463 variant during that week. To compute the total variant-specific infection rate, we then summed  
464 the weekly estimates across all weeks that a given variant was detected. For each variant, to  
465 identify the main circulation period (i.e., calendar weeks when 95% of all infections occurred),  
466 we recorded the first week that the cumulative infection rate surpassed 2.5% (i.e., the start)  
467 and 97.5% (i.e., the end) of the total.

468

#### 469 **Qualitative illustration of immunity from vaccinations and infections by different variants.**

470 The model-inference system accounted for immunity conferred by prior infection and  
471 vaccination and waning (Eq. 1) to compute the posterior estimates of population susceptibility,  
472 using epidemiological data and the EAKF inference algorithm as described above. However,  
473 because the two immune components overlap (e.g., a recoveree could subsequently get  
474 vaccinated and have mixed immunity for both) and the EAKF may not perfectly preserve mass  
475 balance, it is difficult to separately quantify their contributions. Thus, to qualitatively examine  
476 the population immunity landscape, we used the rolling sum of prior infection as a proxy of  
477 infection-induced immunity and that of vaccinations as a proxy of vaccine-induced immunity  
478 (shown in Fig 2B). Specifically, the rolling sum of prior infection was computed by adding all  
479 estimated infections during the preceding  $0.5T_{rs}$  days (i.e., the estimated half time of immunity  
480 period; see Fig S2D). The rolling sum of vaccinations was computed by adding vaccinations of  
481 the primary series, 3<sup>rd</sup>, and 4<sup>th</sup>, 5<sup>th</sup> dose during the preceding  $0.5T_{vax}$  days ( $T_{vax}$  is the estimated  
482 vaccine-induced immunity period) and further multiplying the estimated variant-specific VE  
483 (Table S3).

484  
485 **Acknowledgments:** This study was in part supported by the National Institute of Allergy and  
486 Infectious Diseases (AI145883 and AI175747), the Centers for Disease Control and Prevention  
487 (CDC) and the Council of State and Territorial Epidemiologists (CSTE; contract no.:  
488 NU38OT00297), and the National Science Foundation (DMS-2027369). The authors thank  
489 Lauren Firestein for overseeing the data use agreement and facilitating data sharing for this  
490 project; Ramona Lall for providing syndromic surveillance emergency department data; Iris  
491 Cheng for providing immunization data; Jubayer Ahmed, Nelson De La Cruz, Brandon Nguyen,  
492 and Greta Ohanian for managing and providing wastewater data; Elizabeth Luoma and Rebecca  
493 Rohrer for their management and provision of variant data; the NYC Health Department COVID data  
494 team for overarching data management and provision of data for this project; and Shama  
495 Ahuja, Sharon Greene, Scott Harper, Elizabeth Luoma, Aaron Olson, Enoma Omoregie, Mamta  
496 Parakh, Celia Quinn, Ulrike Siemetzki-Kapoor, Faten Taki, and Gretchen Van Wye for their input  
497 on this manuscript.

498  
499 **Author contributions:** WY designed the study, developed the model-inference system,  
500 performed the analysis, and wrote the first draft; HP and EL provided the COVID-19 case and  
501 emergency department visit data; WL provided the COVID-19-associated mortality data; EAW  
502 provided the SARS-CoV-2 wastewater surveillance data. HY compiled the mobility data. All  
503 authors contributed to the final draft.

504  
505 **Conflict of interest:**  
506 The authors declare that they have no conflict of interest.

507  
508 References:

- 509 1. E. Harris, WHO Declares End of COVID-19 Global Health Emergency. *JAMA-J Am Med*  
510 *Assoc* **329**, (2023).
- 511 2. H. E. Davis, L. McCorkell, J. M. Vogel, E. J. Topol, Long COVID: major findings,  
512 mechanisms and recommendations. *Nat Rev Microbiol* **21**, 133-146 (2023).
- 513 3. K. Koelle, M. A. Martin, R. Antia, B. Lopman, N. E. Dean, The changing epidemiology of  
514 SARS-CoV-2. *Science* **375**, 1116-1121 (2022).
- 515 4. Global Initiative on Sharing All Influenza Data (GISAID), Tracking of hCoV-19 Variants.  
516 <https://www.gisaid.org/hcov19-variants/>
- 517 5. S. Riley, K. E. C. Ainslie, O. Eales, C. E. Walters, H. Wang, C. Atchison, C. Fronterre, P. J.  
518 Diggle, D. Ashby, C. A. Donnelly, G. Cooke, W. Barclay, H. Ward, A. Darzi, P. Elliott,  
519 Resurgence of SARS-CoV-2: Detection by community viral surveillance. *Science* **372**, 990-  
520 995 (2021).
- 521 6. P. Elliott, M. Whitaker, D. Tang, O. Eales, N. Steyn, B. Bodinier, H. Wang, J. Elliott, C.  
522 Atchison, D. Ashby, W. Barclay, G. Taylor, A. Darzi, G. S. Cooke, H. Ward, C. A. Donnelly,

- 523 S. Riley, M. Chadeau-Hyam, Design and Implementation of a National SARS-CoV-2  
524 Monitoring Program in England: REACT-1 Study. *Am J Public Health* **113**, 545-554 (2023).
- 525 7. J. Brainard, I. R. Lake, R. A. Morbey, N. R. Jones, A. J. Elliot, P. R. Hunter, Comparison of  
526 surveillance systems for monitoring COVID-19 in England: a retrospective observational  
527 study. *Lancet Public Health* **8**, e850-e858 (2023).
- 528 8. P. Sah, M. C. Fitzpatrick, C. F. Zimmer, E. Abdollahi, L. Juden-Kelly, S. M. Moghadas, B. H.  
529 Singer, A. P. Galvani, Asymptomatic SARS-CoV-2 infection: A systematic review and  
530 meta-analysis. *Proc Natl Acad Sci U S A* **118**, (2021).
- 531 9. Z. J. Feng, Q. Li, Y. P. Zhang, Z. Y. Wu, X. P. Dong, H. L. Ma, D. P. Yin, K. Lyu, D. Y. Wang, L.  
532 Zhou, R. Q. Ren, C. Li, Y. L. Wang, D. Ni, J. Zhao, B. Li, R. Wang, Y. Niu, X. H. Wang, L. J.  
533 Zhang, J. F. Sun, B. X. Liu, Z. Q. Deng, Z. T. Ma, Y. Yang, H. Liu, G. Shao, H. Li, Y. Liu, H. J.  
534 Zhang, S. Q. Qu, W. Lou, D. Shan, Y. H. Hu, L. Hou, Z. P. Zhao, J. M. Liu, H. Y. Wang, Y. J.  
535 Pang, Y. T. Han, Q. Y. Ma, Y. J. Ma, S. Chen, W. Li, R. T. Yang, Z. W. Li, Y. N. Guo, X. R. Liu,  
536 B. Jiangtulu, Z. X. Yin, J. Xu, S. Wang, L. Xiao, T. Xu, L. M. Wang, X. Qi, G. Q. Shi, W. X. Tu,  
537 X. M. Shi, X. M. Su, Z. J. Li, H. M. Luo, J. Q. Ma, J. M. McGoogan, The Epidemiological  
538 Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) - China,  
539 2020. *China CDC Weekly* **2**, 113-122 (2020).
- 540 10. B. Rader, A. Gertz, A. D. Iuliano, M. Gilmer, L. Wronski, C. M. Astley, K. Sewalk, T. J.  
541 Varrelman, J. Cohen, R. Parikh, Use of At-Home COVID-19 Tests—United States, August  
542 23, 2021–March 12, 2022. *Morbidity and Mortality Weekly Report* **71**, 489 (2022).
- 543 11. W. Yang, J. Shaff, J. Shaman, Effectiveness of non-pharmaceutical interventions to  
544 contain COVID-19: a case study of the 2020 spring pandemic wave in New York City. *J R*  
545 *Soc Interface* **18**, 20200822 (2021).
- 546 12. W. Yang, S. Kandula, M. Huynh, S. K. Greene, G. Van Wye, W. Li, H. T. Chan, E.  
547 McGibbon, A. Yeung, D. Olson, A. Fine, J. Shaman, Estimating the infection-fatality risk of  
548 SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based  
549 analysis. *The Lancet Infectious Diseases* **21**, 203-212 (2021).
- 550 13. W. Yang, S. K. Greene, E. R. Peterson, W. Li, R. Mathes, L. Graf, R. Lall, S. Hughes, J.  
551 Wang, A. Fine, Epidemiological characteristics of the B.1.526 SARS-CoV-2 variant.  
552 *Science Advances* **8**, eabm0300 (2022).
- 553 14. The New York Times, New York City says it will end school mask and indoor proof-of-  
554 vaccination mandates. [https://www.nytimes.com/2022/02/27/nyregion/new-york-](https://www.nytimes.com/2022/02/27/nyregion/new-york-mask-mandate-schools.html)  
555 [mask-mandate-schools.html](https://www.nytimes.com/2022/02/27/nyregion/new-york-mask-mandate-schools.html)
- 556 15. P. Mlcochova, S. A. Kemp, M. S. Dhar, G. Papa, B. Meng, I. Ferreira, R. Datir, D. A. Collier,  
557 A. Albecka, S. Singh, R. Pandey, J. Brown, J. Zhou, N. Goonawardane, S. Mishra, C.  
558 Whittaker, T. Mellan, R. Marwal, M. Datta, S. Sengupta, K. Ponnusamy, V. S.  
559 Radhakrishnan, A. Abdullahi, O. Charles, P. Chattopadhyay, P. Devi, D. Caputo, T.  
560 Peacock, C. Wattal, N. Goel, A. Satwik, R. Vaishya, M. Agarwal, S.-C.-G. C. Indian, C.  
561 Genotype to Phenotype Japan, C.-N. B. C.-. Collaboration, A. Mavousian, J. H. Lee, J.  
562 Bassi, C. Silacci-Fegni, C. Saliba, D. Pinto, T. Irie, I. Yoshida, W. L. Hamilton, K. Sato, S.  
563 Bhatt, S. Flaxman, L. C. James, D. Corti, L. Piccoli, W. S. Barclay, P. Rakshit, A. Agrawal, R.  
564 K. Gupta, SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. *Nature*  
565 **599**, 114-119 (2021).

- 566 16. J. L. Bernal, N. Andrews, C. Gower, E. Gallagher, R. Simmons, S. Thelwall, J. Stowe, E.  
567 Tessier, N. Groves, G. Dabrera, R. Myers, C. N. J. Campbell, G. Amirthalingam, M.  
568 Edmunds, M. Zambon, K. E. Brown, S. Hopkins, M. Chand, M. Ramsay, Effectiveness of  
569 Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *New England Journal of*  
570 *Medicine* **385**, 585-594 (2021).
- 571 17. W. Yang, J. L. Shaman, COVID-19 pandemic dynamics in South Africa and  
572 epidemiological characteristics of three variants of concern (Beta, Delta, and Omicron).  
573 *Elife* **11**, e78933 (2022).
- 574 18. S. Cele, L. Jackson, D. S. Khoury, K. Khan, T. Moyo-Gwete, H. Tegally, J. E. San, D. Cromer,  
575 C. Scheepers, D. G. Amoako, F. Karim, M. Bernstein, G. Lustig, D. Archary, M. Smith, Y.  
576 Ganga, Z. Jule, K. Reedoy, S.-H. Hwa, J. Giandhari, J. M. Blackburn, B. I. Gosnell, S. S.  
577 Abdool Karim, W. Hanekom, M.-A. Davies, M. Hsiao, D. Martin, K. Mlisana, C. K. Wibmer,  
578 C. Williamson, D. York, R. Harrichandparsad, K. Herbst, P. Jeena, T. Khoza, H. Kløverpris,  
579 A. Leslie, R. Madansein, N. Magula, N. Manickchund, M. Marakalala, M. Mazibuko, M.  
580 Moshabela, N. Mthabela, K. Naidoo, Z. Ndhlovu, T. Ndung'u, N. Ngcobo, K. Nyamande,  
581 V. Patel, T. Smit, A. Steyn, E. Wong, A. von Gottberg, J. N. Bhiman, R. J. Lessells, M.-Y. S.  
582 Moosa, M. P. Davenport, T. de Oliveira, P. L. Moore, A. Sigal, Omicron extensively but  
583 incompletely escapes Pfizer BNT162b2 neutralization. *Nature* **602**, 654-656 (2022).
- 584 19. J. R. C. Pulliam, C. van Schalkwyk, N. Govender, A. von Gottberg, C. Cohen, M. J.  
585 Groome, J. Dushoff, K. Mlisana, H. Moultrie, Increased risk of SARS-CoV-2 reinfection  
586 associated with emergence of Omicron in South Africa. *Science* **376**, eabn4947 (2022).
- 587 20. Q. Wang, Y. Guo, S. Iketani, M. S. Nair, Z. Li, H. Mohri, M. Wang, J. Yu, A. D. Bowen, J. Y.  
588 Chang, J. G. Shah, N. Nguyen, Z. Chen, K. Meyers, M. T. Yin, M. E. Sobieszczyk, Z. Sheng,  
589 Y. Huang, L. Liu, D. D. Ho, Antibody evasion by SARS-CoV-2 Omicron subvariants  
590 BA.2.12.1, BA.4 and BA.5. *Nature* **608**, 603-608 (2022).
- 591 21. Y. Cao, A. Yisimayi, F. Jian, W. Song, T. Xiao, L. Wang, S. Du, J. Wang, Q. Li, X. Chen, Y. Yu,  
592 P. Wang, Z. Zhang, P. Liu, R. An, X. Hao, Y. Wang, J. Wang, R. Feng, H. Sun, L. Zhao, W.  
593 Zhang, D. Zhao, J. Zheng, L. Yu, C. Li, N. Zhang, R. Wang, X. Niu, S. Yang, X. Song, Y. Chai,  
594 Y. Hu, Y. Shi, L. Zheng, Z. Li, Q. Gu, F. Shao, W. Huang, R. Jin, Z. Shen, Y. Wang, X. Wang,  
595 J. Xiao, X. S. Xie, BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron  
596 infection. *Nature* **608**, 593-602 (2022).
- 597 22. W. Yang, J. Shaman, Development of a model-inference system for estimating  
598 epidemiological characteristics of SARS-CoV-2 variants of concern. *Nature*  
599 *Communications* **12**, 5573 (2021).
- 600 23. R. Anderson, C. Donnelly, D. Hollingsworth, M. Keeling, C. Vegvari, R. Baggaley, R.  
601 Maddren, Reproduction number (R) and growth rate (r) of the COVID-19 epidemic in the  
602 UK: methods of estimation, data sources, causes of heterogeneity, and use as a guide in  
603 policy formulation. *The Royal Society* **2020**, (2020).
- 604 24. E. Volz, S. Mishra, M. Chand, J. C. Barrett, R. Johnson, L. Geidelberg, W. R. Hinsley, D. J.  
605 Laydon, G. Dabrera, A. O'Toole, R. Amato, M. Ragonnet-Cronin, I. Harrison, B. Jackson, C.  
606 V. Ariani, O. Boyd, N. J. Loman, J. T. McCrone, S. Goncalves, D. Jorgensen, R. Myers, V.  
607 Hill, D. K. Jackson, K. Gaythorpe, N. Groves, J. Sillitoe, D. P. Kwiatkowski, C.-G. U.  
608 consortium, S. Flaxman, O. Ratmann, S. Bhatt, S. Hopkins, A. Gandy, A. Rambaut, N. M.



- 609 Ferguson, Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. *Nature*  
610 **593**, 266-269 (2021).
- 611 25. D. H. Morris, K. C. Yinda, A. Gamble, F. W. Rossine, Q. Huang, T. Bushmaker, R. J. Fischer,  
612 M. J. Matson, N. Van Doremalen, P. J. Vikesland, L. C. Marr, V. J. Munster, J. O. Lloyd-  
613 Smith, Mechanistic theory predicts the effects of temperature and humidity on  
614 inactivation of SARS-CoV-2 and other enveloped viruses. *Elife* **10**, (2021).
- 615 26. L. C. Marr, J. W. Tang, J. Van Mullekom, S. S. Lakdawala, Mechanistic insights into the  
616 effect of humidity on airborne influenza virus survival, transmission and incidence. *J R*  
617 *Soc Interface* **16**, (2019).
- 618 27. W. Yang, L. C. Marr, Mechanisms by which ambient humidity may affect viruses in  
619 aerosols. *Appl Environ Microbiol* **78**, 6781-6788 (2012).
- 620 28. E. Huynh, A. Olinger, D. Woolley, R. K. Kohli, J. M. Choczynski, J. F. Davies, K. Lin, L. C.  
621 Marr, R. D. Davis, Evidence for a semisolid phase state of aerosols and droplets relevant  
622 to the airborne and surface survival of pathogens. *Proc Natl Acad Sci U S A* **119**, (2022).
- 623 29. L. Morawska, J. W. Tang, W. Bahnfleth, P. M. Bluysen, A. Boerstra, G. Buonanno, J. Cao,  
624 S. Dancer, A. Floto, F. Franchimon, C. Haworth, J. Hogeling, C. Isaxon, J. L. Jimenez, J.  
625 Kurnitski, Y. Li, M. Loomans, G. Marks, L. C. Marr, L. Mazzeola, A. K. Melikov, S. Miller,  
626 D. K. Milton, W. Nazaroff, P. V. Nielsen, C. Noakes, J. Peccia, X. Querol, C. Sekhar, O.  
627 Seppänen, S.-i. Tanabe, R. Tellier, K. W. Tham, P. Wargocki, A. Wierzbicka, M. Yao, How  
628 can airborne transmission of COVID-19 indoors be minimised? *Environment*  
629 *International* **142**, 105832 (2020).
- 630 30. T. W. Russell, N. Golding, J. Hellewell, S. Abbott, L. Wright, C. A. B. Pearson, K. van  
631 Zandvoort, C. I. Jarvis, H. Gibbs, Y. Liu, R. M. Eggo, W. J. Edmunds, A. J. Kucharski, C. C.-  
632 w. group, Reconstructing the early global dynamics of under-ascertained COVID-19  
633 cases and infections. *BMC Med* **18**, 332 (2020).
- 634 31. A. T. Levin, W. P. Hanage, N. Owusu-Boaitey, K. B. Cochran, S. P. Walsh, G. Meyerowitz-  
635 Katz, Assessing the age specificity of infection fatality rates for COVID-19: systematic  
636 review, meta-analysis, and public policy implications. *Eur J Epidemiol* **35**, 1123-1138  
637 (2020).
- 638 32. M. O'Driscoll, G. R. Dos Santos, L. Wang, D. A. T. Cummings, A. S. Azman, J. Paireau, A.  
639 Fontanet, S. Cauchemez, H. Salje, Age-specific mortality and immunity patterns of SARS-  
640 CoV-2. *Nature*, (2020).
- 641 33. W. S. Hoogenboom, A. Pham, H. Anand, R. Fleysheer, A. Buczek, S. Soby, P. Mirhaji, J. Yee,  
642 T. Q. Duong, Clinical characteristics of the first and second COVID-19 waves in the Bronx,  
643 New York: A retrospective cohort study. *Lancet Reg Health Am* **3**, 100041 (2021).
- 644 34. N. G. Davies, C. I. Jarvis, C. C.-W. Group, W. J. Edmunds, N. P. Jewell, K. Diaz-Ordaz, R. H.  
645 Keogh, Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7.  
646 *Nature* **593**, 270-274 (2021).
- 647 35. N. Wolter, W. Jassat, S. Walaza, R. Welch, H. Moultrie, M. Groome, D. G. Amoako, J.  
648 Everatt, J. N. Bhiman, C. Scheepers, N. Tebeila, N. Chiwandire, M. du Plessis, N.  
649 Govender, A. Ismail, A. Glass, K. Mlisana, W. Stevens, F. K. Treurnicht, Z. Makatini, N.-y.  
650 Hsiao, R. Parboosing, J. Wadula, H. Hussey, M.-A. Davies, A. Boule, A. von Gottberg, C.  
651 Cohen, Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in  
652 South Africa: a data linkage study. *The Lancet* **399**, 437-446 (2022).


- 653 36. National Academies of Sciences, Engineering, and Medicine, *Long-Term Health Effects of*  
654 *COVID-19: Disability and Function Following SARS-CoV-2 Infection*. P. A. Volberding, B. X.  
655 Chu, C. M. Spicer, Eds., (The National Academies Press, Washington, DC, 2024), pp. 264.
- 656 37. L. Ungar, Pandemic gets tougher to track as COVID testing plunges.  
657 [https://apnews.com/article/covid-us-testing-decline-](https://apnews.com/article/covid-us-testing-decline-14bf5b0901260b063e4fa444633f4d31)  
658 [14bf5b0901260b063e4fa444633f4d31](https://apnews.com/article/covid-us-testing-decline-14bf5b0901260b063e4fa444633f4d31)
- 659 38. M. Kekatos, COVID call centers and testing sites close in further sign US is moving past  
660 the pandemic. [https://abcnews.go.com/Health/covid-call-centers-testing-sites-close-](https://abcnews.go.com/Health/covid-call-centers-testing-sites-close-sign-us/story?id=97580639)  
661 [sign-us/story?id=97580639](https://abcnews.go.com/Health/covid-call-centers-testing-sites-close-sign-us/story?id=97580639)
- 662 39. R. Stein, As the pandemic ebbs, an influential COVID tracker shuts down.  
663 [https://www.npr.org/sections/health-shots/2023/02/10/1155790201/as-the-pandemic-](https://www.npr.org/sections/health-shots/2023/02/10/1155790201/as-the-pandemic-ebbs-an-influential-covid-tracker-shuts-down)  
664 [ebbs-an-influential-covid-tracker-shuts-down](https://www.npr.org/sections/health-shots/2023/02/10/1155790201/as-the-pandemic-ebbs-an-influential-covid-tracker-shuts-down)
- 665 40. B. J. Silk, H. M. Scobie, W. M. Duck, T. Palmer, F. B. Ahmad, A. M. Binder, J. A. Cisewski,  
666 S. Kroop, K. Soetebier, M. Park, A. Kite-Powell, A. Cool, E. Connelly, S. Dietz, A. E. Kirby,  
667 K. Hartnett, J. Johnston, D. Khan, S. Stokley, C. R. Paden, M. Sheppard, P. Sutton, H.  
668 Razzaghi, R. N. Anderson, N. Thornburg, S. Meyer, C. Womack, A. P. Weakland, M.  
669 McMorrow, L. R. Broeker, A. Winn, A. J. Hall, B. Jackson, B. E. Mahon, M. D. Ritchey,  
670 COVID-19 Surveillance After Expiration of the Public Health Emergency Declaration-  
671 United States, May 11, 2023. *Mmwr-Morbid Mortal W* **72**, 523-528 (2023).
- 672 41. The Council of State and Territorial Epidemiologists, Association of Public Health  
673 Laboratories, Interim CSTE and APHL Strategic Framework for SARS-CoV-2 Infection and  
674 COVID-19 Surveillance: Priorities and Approaches for State, Territorial, Local, and Tribal  
675 Public Health Agencies. [https://preparedness.cste.org/wp-](https://preparedness.cste.org/wp-content/uploads/2022/10/Interim-CSTE-APHL-COVID-Surveillance-Framework.pdf)  
676 [content/uploads/2022/10/Interim-CSTE-APHL-COVID-Surveillance-Framework.pdf](https://preparedness.cste.org/wp-content/uploads/2022/10/Interim-CSTE-APHL-COVID-Surveillance-Framework.pdf)
- 677 42. W. Yang, J. Shaff, J. Shaman, Effectiveness of non-pharmaceutical interventions to  
678 contain COVID-19: a case study of the 2020 spring pandemic wave in New York City. *J R*  
679 *Soc Interface* **18**, 20200822 (2021).
- 680 43. A. Lasry, D. Kidder, M. Hast, J. Poovey, G. Sunshine, K. Winglee, N. Zviedrite, F. Ahmed,  
681 K. A. Ethier, CDC Public Health Law Program, New York City Department of Health and  
682 Mental Hygiene, Louisiana Department of Health, Public Health Seattle and King County,  
683 San Francisco COVID-Response Team, Alameda County Public Health Department, San  
684 Mateo County Health Department, Marin County Division of Public Health, Timing of  
685 Community Mitigation and Changes in Reported COVID-19 and Community Mobility -  
686 Four U.S. Metropolitan Areas, February 26-April 1, 2020. *MMWR. Morbidity and*  
687 *mortality weekly report* **69**, 451-457 (2020).
- 688 44. M. U. G. Kraemer, C. H. Yang, B. Gutierrez, C. H. Wu, B. Klein, D. M. Pigott, C.-D. W. G.  
689 Open, L. du Plessis, N. R. Faria, R. Li, W. P. Hanage, J. S. Brownstein, M. Layan, A.  
690 Vespignani, H. Tian, C. Dye, O. G. Pybus, S. V. Scarpino, The effect of human mobility and  
691 control measures on the COVID-19 epidemic in China. *Science* **368**, 493-497 (2020).
- 692 45. R. Li, S. Pei, B. Chen, Y. Song, T. Zhang, W. Yang, J. Shaman, Substantial undocumented  
693 infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). *Science*  
694 **368**, 489-493 (2020).
- 695 46. P. M. DeJonge, Wastewater surveillance data as a complement to emergency  
696 department visit data for tracking incidence of influenza A and respiratory syncytial

- 697 virus—Wisconsin, August 2022–March 2023. *MMWR. Morbidity and Mortality Weekly*  
698 *Report* **72**, (2023).
- 699 47. SafeGraph, Weekly Patterns: Foot Traffic Data To Understand The COVID-19 Pandemic.  
700 <https://www.safegraph.com/weekly-foot-traffic-patterns>
- 701 48. Centers for Disease Control and Prevention, National Notifiable Diseases Surveillance  
702 System (NNDSS) - Coronavirus Disease 2019 (COVID-19).  
703 <https://ndc.services.cdc.gov/conditions/coronavirus-disease-2019-covid-19/>
- 704 49. New York City Department of Health and Mental Hygiene, Defining confirmed and  
705 probable cases and deaths. <https://www1.nyc.gov/site/doh/covid/covid-19-data.page>
- 706 50. R. Lall, J. Abdelnabi, S. Ngai, H. B. Parton, K. Saunders, J. Sell, A. Wahnich, D. Weiss, R. W.  
707 Mathes, Advancing the Use of Emergency Department Syndromic Surveillance Data,  
708 New York City, 2012-2016. *Public Health Rep* **132**, 23s-30s (2017).
- 709 51. New York City Department of Health and Mental Hygiene, NYC UHF 42 Neighborhoods.  
710 <http://a816-dohbexp.nyc.gov/IndicatorPublic/EPHTPDF/uhf42.pdf>
- 711 52. New York City Department of Health and Mental Hygiene (DOHMH) COVID-19 Response  
712 Team, Preliminary Estimate of Excess Mortality During the COVID-19 Outbreak — New  
713 York City, March 11–May 2, 2020. *MMWR. Morbidity and mortality weekly report* **69**,  
714 603-605 (2020).
- 715 53. New York City Department of Health and Mental Hygiene, NYC Coronavirus Disease  
716 2019 (COVID-19) Data. 1/10/2024. <https://github.com/nychealth/coronavirus-data>
- 717 54. New York City Department of Health and Mental Hygiene, NYC Coronavirus 2019  
718 (COVID-19) Vaccine Data. <https://github.com/nychealth/covid-vaccine-data>
- 719 55. C. N. Thompson, S. Hughes, S. Ngai, J. Baumgartner, J. C. Wang, E. McGibbon, K.  
720 Devinney, E. Luoma, D. Bertolino, C. Hwang, K. Kepler, C. Del Castillo, M. Hopkins, H.  
721 Lee, A. K. DeVito, J. L. Rakeman, PhD, A. D. Fine, Rapid Emergence and Epidemiologic  
722 Characteristics of the SARS-CoV-2 B.1.526 Variant - New York City, New York, January 1-  
723 April 5, 2021. *MMWR Morb Mortal Wkly Rep* **70**, 712-716 (2021).
- 724 56. New York City Department of Health and Mental Hygiene, Variants.  
725 <https://github.com/nychealth/coronavirus-data/tree/master/variants>
- 726 57. W. Yang, J. Shaman, Development of Accurate Long-lead COVID-19 Forecast. *PLoS*  
727 *Comput Biol* **19**, e1011278 (2023).
- 728 58. New York City Department of Health and Mental Hygiene, NYC DOHMH population  
729 estimates, modified from US Census Bureau interpolated intercensal population  
730 estimates, 2000-2018. Updated August 2019.
- 731 59. J. X. Benjamin J Cowling, Escandón, Re: Effectiveness of public health measures in  
732 reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality:  
733 systematic review and meta-analysis. *BMJ*, (2021).  
734 <https://www.bmj.com/content/375/bmj-2021-068302/rr-14>).
- 735 60. F. P. Polack, S. J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J. L. Perez, G.  
736 Perez Marc, E. D. Moreira, C. Zerbini, R. Bailey, K. A. Swanson, S. Roychoudhury, K.  
737 Koury, P. Li, W. V. Kalina, D. Cooper, R. W. Frenck, Jr., L. L. Hammitt, O. Tureci, H. Nell, A.  
738 Schaefer, S. Unal, D. B. Tresnan, S. Mather, P. R. Dormitzer, U. Sahin, K. U. Jansen, W. C.  
739 Gruber, C. C. T. Group, Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N*  
740 *Engl J Med* **383**, 2603-2615 (2020).


- 741 61. L. R. Baden, H. M. El Sahly, B. Essink, K. Kotloff, S. Frey, R. Novak, D. Diemert, S. A.  
742 Spector, N. Rouphael, C. B. Creech, J. McGettigan, S. Khetan, N. Segall, J. Solis, A. Brosz,  
743 C. Fierro, H. Schwartz, K. Neuzil, L. Corey, P. Gilbert, H. Janes, D. Follmann, M. Marovich,  
744 J. Mascola, L. Polakowski, J. Ledgerwood, B. S. Graham, H. Bennett, R. Pajon, C. Knightly,  
745 B. Leav, W. Deng, H. Zhou, S. Han, M. Ivarsson, J. Miller, T. Zaks, C. S. Group, Efficacy and  
746 Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* **384**, 403-416 (2021).
- 747 62. E. J. Haas, F. J. Angulo, J. M. McLaughlin, E. Anis, S. R. Singer, F. Khan, N. Brooks, M.  
748 Smaja, G. Mircus, K. Pan, J. Southern, D. L. Swerdlow, L. Jodar, Y. Levy, S. Alroy-Preis,  
749 Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and  
750 COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination  
751 campaign in Israel: an observational study using national surveillance data. *The Lancet*  
752 **397**, 1819-1829 (2021).
- 753 63. UK Health Security Agency, COVID-19 vaccine surveillance report (Week 17, 28 April  
754 2022).  
755 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachm](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1072064/Vaccine-surveillance-report-week-17.pdf)  
756 [ent\\_data/file/1072064/Vaccine-surveillance-report-week-17.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1072064/Vaccine-surveillance-report-week-17.pdf)
- 757 64. F. C. M. Kirsebom, N. Andrews, J. Stowe, S. Toffa, R. Sachdeva, E. Gallagher, N. Groves,  
758 A.-M. O'Connell, M. Chand, M. Ramsay, J. L. Bernal, COVID-19 vaccine effectiveness  
759 against the omicron (BA.2) variant in England. *The Lancet Infectious Diseases*.
- 760 65. J. L. Anderson, An ensemble adjustment Kalman filter for data assimilation. *Mon.*  
761 *Weather Rev.* **129**, 2884-2903 (2001).  
762

## Figures


**Fig 1.** Model fit and validation. (A) Model fit to weekly number of COVID-19 cases, emergency department (ED) visits, and deaths, during the week starting 03/01/20 (mm/dd/yy) to the week starting 08/27/23 (see x-axis). Blue lines show the median estimates and blue areas show 50% (darker) and 95% (lighter) credible intervals (CrIs); dots show the corresponding observations. (B) Model validation using wastewater surveillance data, for the 2<sup>nd</sup> wave (left panel), Delta wave (middle panel), the Omicron period (right panel). Lines and shaded areas show the estimated infection prevalence (i.e., the number of all infectious individuals including those not detected as cases; median, 50% and 95% CrIs; left y-axis). Dots show measured SARS-CoV-2 concentrations in wastewater (right y-axis, in million copies per day per population) for the corresponding weeks (black dots show measurements using RT-qPCR and red dots show measurements using RT-dPCR but converted to RT-qPCR equivalents; note that the wastewater concentrations are scaled for each wave/period to facilitate comparison with model estimates; see Methods for details).




**Fig 2.** Estimated infection rates (A), population immunity dynamics (B), and virus transmissibility (C). In (A), colored bars show estimated median weekly infection rates, for each variant (see legends). In (B), we overlay estimated population susceptibility [left y-axis; blue line = median, blue areas = 50% (darker) and 95% (lighter) CrIs], and proxies of cumulative infection (colored stacked bars from top to bottom, right y-axis; same legends as in A for different variants) and vaccine-induced immunity against infection (open bars; see Methods). In (C), we show estimated virus transmissibility [left y-axis; blue line = median, blue areas = 50% (darker) and 95% (lighter) CrIs] and infection rates [boxplot and right y-axis; middle bar = median, edges = 50% CrIs, and whiskers = 95% CrIs] for the corresponding weeks.



**Fig 3.** Infection annual pattern and detection rates. (A) shows estimated infection rates (light blue bars, full height; i.e., not stacked) and reported case rates (darker blue portion) by month; error bars show estimated 95% CIs. To examine the infection annual pattern, (B) shows the monthly infection rates scaled to the annual maximum (here, a year starts in September, the start of fall/cold months in the Northern hemisphere, and ends in the next August, the end of winter/cold months in Southern hemisphere). March – August 2020 is not shown due to the incompleteness. (C) shows estimated infection-detection rate [blue line = median, blue areas = 50% (darker) and 95% (lighter) CIs], for each week. Note the vertical dashed line indicates the week starting 11/21/21 when Omicron BA.1 was first detected in NYC, and estimates to the right of the dashed line are for Omicron (sub)variants alone.



**Fig 4.** Estimated infection-fatality risk (IFR) over time, by age group (A-E) and overall (F). Blue lines and shaded areas show the median estimates and 50% (darker blue) and 95% (lighter blue) CrIs, for each week (see date of week start in mm/dd/yy in the x-axis). For clarity, insets show estimates during the most recent months.





**Table 1.** Estimated cumulative infection rate, by variant. For ease of comparison, we convert the number of detected cases and estimated infections to percentage relative to the size of NYC’s population (columns labeled “% population”), i.e., this percentage does not refer to unique individuals detected as cases or estimated to experience infections.

Variant	Main circulation period	Cases detected		Estimated infections	
		n (×1000) <sup>a</sup>	% population <sup>b</sup>	n (×1000) <sup>a</sup>	% population <sup>b</sup>
All		3,207	38.2%	17,383 (14,154, 21,549)	207% (168.5%, 256.6%)
Pre-Omicron		1,162	13.8%	4,509 (3,673, 5,423)	53.7% (43.7%, 64.6%)
Omicron		2,046	24.4%	12,875 (10,481, 16,126)	153.3% (124.8%, 192%)
BA.1	12/12/2021 - 02/05/2022	1,024	12%	3,468 (2,188, 5,624)	41.3% (26.1%, 67%)
Ancestral/Iota	03/08/2020 - 04/17/2021	834	9.9%	3,195 (1,653, 6,334)	38% (19.7%, 75.4%)
BA.5	06/05/2022 - 12/03/2022	289	3.4%	2,107 (1,148, 4,589)	25.1% (13.7%, 54.6%)
XBB.1.5	11/27/2022 - 08/12/2023	175	2.1%	1,783 (790, 5,018)	21.2% (9.4%, 59.7%)
BA.2.12.1	04/10/2022 - 07/16/2022	145	1.7%	881 (462, 1,948)	10.5% (5.5%, 23.2%)
Delta	06/27/2021 - 12/11/2021	225	2.7%	704 (327, 1,792)	8.4% (3.9%, 21.3%)
BA.2	02/13/2022 - 07/23/2022	128	1.5%	621 (332, 1,375)	7.4% (4%, 16.4%)
BQ.1	10/02/2022 - 01/07/2023	61	0.73%	591 (311, 1,338)	7% (3.7%, 15.9%)
BQ.1.1	10/09/2022 - 01/28/2023	58	0.7%	566 (295, 1,287)	6.7% (3.5%, 15.3%)
XBB	10/23/2022 - 09/02/2023	37	0.44%	439 (214, 1,181)	5.2% (2.5%, 14.1%)
FL.1	05/07/2023 - 09/02/2023	13	0.16%	243 (117, 709)	2.9% (1.4%, 8.4%)
Alpha	01/17/2021 - 06/12/2021	77	0.92%	240 (128, 471)	2.9% (1.5%, 5.6%)
BA.4.6	06/19/2022 - 11/19/2022	32	0.39%	238 (130, 523)	2.8% (1.5%, 6.2%)
XBB.1.16	04/23/2023 - 09/02/2023	13	0.16%	234 (100, 802)	2.8% (1.2%, 9.5%)
BA.4	05/22/2022 - 09/24/2022	32	0.39%	223 (121, 481)	2.7% (1.4%, 5.7%)
EG.5	05/21/2023 - 09/02/2023	11	0.14%	209 (99, 617)	2.5% (1.2%, 7.3%)
BA.2.75	09/04/2022 - 08/19/2023	13	0.15%	124 (62, 310)	1.5% (0.7%, 3.7%)
XBB.1.9	03/05/2023 - 09/02/2023	5	0.056%	75 (30, 268)	0.9% (0.4%, 3.2%)
BF.7	08/07/2022 - 12/24/2022	8	0.1%	74 (38, 172)	0.9% (0.5%, 2%)
Epsilon	12/27/2020 - 04/17/2021	10	0.11%	25 (15, 45)	0.3% (0.2%, 0.5%)
Gamma	03/21/2021 - 07/17/2021	4	0.052%	16 (8, 38)	0.2% (0.1%, 0.5%)
Mu	04/11/2021 - 09/25/2021	3	0.035%	12 (6, 33)	0.1% (0.1%, 0.4%)


<sup>a</sup>The numbers are shown in thousands (i.e., ×1000). <sup>b</sup>The percentages are relative to the city’s population size of 8.39 million residents.

**Table 2.** Estimated virus transmissibility ( $R_{TX}$ ) and overall infection-fatality risk (IFR) during each wave/period. Numbers show the median estimate (and 95% credible intervals). Note the calendar periods here were chosen based on the rough timing of pandemic waves (March – May 2020 for the 1<sup>st</sup> wave, October 2020 – May 2021 for the 2<sup>nd</sup> wave, July – November 2021 for the Delta wave, and December 2021 – August 2023 for Omicron subvariants; see Fig 1), matching with the weekly intervals (hence the listed start dates) and excluding weeks with mixed circulation of variants (hence the missing weeks) in order to obtain more variant-specific estimates.


Wave/variants	Calendar period	$R_{TX}$	IFR (%)
1st wave (ancestral)	03/01/20 - 05/30/20	2.4 (1.33-3.68)	1.429 (0.979-1.903)
2nd wave (ancestral/Iota/Alpha)	10/04/20 - 05/29/21	2.86 (1.73- 4.29)	0.397 (0.246-0.6)
Delta	07/04/21 - 12/04/21	3.75 (2.12- 5.75)	0.241 (0.094-0.602)
Omicron BA.1	12/12/21 - 02/26/22	5.46 (3.73- 7.35)	0.095 (0.047-0.166)
After BA.1	03/06/22 - 09/02/23	6.38 (4.15- 9.37)	0.056 (0.022-0.136)

## Supplemental Figures and Tables


**Fig S1.** Model fits by age group. Boxplots show model estimates of COVID-19 cases (A and B), ED visits (C and D), and deaths (E and F) per 100,000 population (middle bar = median, edges = 50% CrIs, and whiskers = 95% CrIs), for each age group (see subtitle) and week (see x-axis, mm/dd/yy). Red dots show the corresponding observations.



**Fig S2.** Estimates for key epidemiological variables: (A) the real-time effective reproduction number  $R_t$ , (B) citywide transmission rate ( $\beta_{city}$  in Eq. 1) (C) infectious period, and (D) immunity period ( $T_{rs}$  in Eq. 1). Blue lines and shaded areas show the median estimates and 50% (darker blue) and 95% (lighter blue) CrIs, for each week (see date of week start in mm/dd/yy in the x-axis). The vertical dashed line indicates the week starting 11/21/21 when Omicron BA.1 was first detected in NYC.



**Fig S3.** Trends in population mobility during the study period. Relative mobility for each week is computed by dividing the mobility for each week by that during the week starting March 1, 2020 (i.e., the pandemic onset in NYC). SafeGraph data were available from the week of March 1, 2020 to the week of December 19, 2022 (red solid line), and used in this study. For the week of December 26, 2022 to the week of August 27, 2023, we used trends constructed with historical SafeGraph data (i.e., weeks during March 2020 – December 2022, using the maximum mobility recorded for the corresponding week of year to account for seasonal changes; red dashed line). Real-time subway ridership data (blue line) are shown for comparison.



**Table S1.** Estimated infection-fatality risk (IFR, %), for individual age groups, during each wave/period. Numbers show the median estimate (and 95% credible intervals). The last two rows show stratified estimates for weeks post-BA.1, before and after the revision of COVID-19 death definition following the recommendation of the Council of State and Territorial Epidemiologists (CSTE).

Wave/variants	Calendar period	all ages	<25 years	25-44 years	45-64 years	65-74 years	75+ years
1st wave (ancestral)	03/01/20 - 05/30/20	1.4291 (0.9793-1.903)	0.0099 (0.0046- 0.0151)	0.1117 (0.0706- 0.1466)	1.1992 (0.8047- 1.5056)	4.6334 (2.7199- 6.9133)	12.2835 (7.3515- 16.9023)
2nd wave (ancestral/Iota/Alpha)	10/04/20 - 05/29/21	0.3965 (0.2461- 0.6004)	0.0047 (0.0019- 0.0088)	0.0379 (0.0174- 0.0673)	0.324 (0.2013- 0.5231)	1.9044 (0.9849- 3.1934)	5.5573 (3.238- 7.5487)
Delta	07/04/21 - 12/04/21	0.2406 (0.0936- 0.6016)	0.004 (0.0019- 0.0061)	0.04 (0.0209- 0.0598)	0.3436 (0.1906- 0.5516)	0.9821 (0.2883- 2.6949)	2.4551 (0.9768- 5.4612)
Omicron BA.1	12/12/21 - 02/26/22	0.0945 (0.0474- 0.1663)	0.0017 (6e-04- 0.0029)	0.0106 (0.0042- 0.0202)	0.0842 (0.0441- 0.147)	0.3921 (0.2286- 0.5353)	1.5588 (0.9388- 2.1269)
After BA.1 (all weeks)	03/06/22 - 09/02/23	0.0561 (0.0219- 0.1355)	0.0018 (5e-04- 0.0032)	0.0098 (0.0016- 0.0208)	0.0352 (0.0071- 0.1249)	0.1457 (0.0471- 0.3591)	0.4927 (0.2496- 1.0303)
After BA.1 (before revision of COVID-19 death definition) <sup>a</sup>	03/06/22 - 04/22/23	0.0621 (0.0274- 0.1349)	0.0018 (5e-04- 0.0032)	0.0095 (0.0018- 0.0202)	0.0357 (0.0083- 0.1207)	0.1587 (0.0588-0.358)	0.5885 (0.3186- 1.0814)
After BA.1 (after revision of COVID-19 death definition) <sup>b</sup>	04/23/23 - 09/02/23	0.0373 (0.0048- 0.1375)	0.0017 (3e-04- 0.0034)	0.0109 (0.0012- 0.0227)	0.0337 (0.0036- 0.138)	0.1055 (0.0107- 0.3625)	0.1951 (0.0355- 0.8716)

<sup>a</sup>Before April 22, 2023, COVID-19-associated deaths included deaths occurring in persons with laboratory-confirmed SARS-CoV-2 infection, and deaths with COVID-19, SARS-CoV-2, or a similar term listed on the death certificate as an immediate, underlying, or contributing cause of death but did not have laboratory-confirmation of COVID-19.

<sup>b</sup>From April 23, 2023 onward, COVID-19-associated deaths included any death where the death certificate includes COVID-19 or a common variation of COVID-19, SARS-CoV-2, coronavirus, etc.

**Table S2.** Correlation between infection-detection rate and population mobility, during the early weeks of the 1<sup>st</sup> pandemic wave and the Omicron BA.1 wave. Numbers show the mean (and 95% confidence intervals [CI]) of Pearson’s correlation coefficients during the first 4, 6, and 8 weeks (column “First N weeks”) of the two pandemic waves. These results show estimated infection-detection rates were negatively correlated with observed population mobility during the early weeks of both pandemic waves; that is, initial increases in community mitigation via social distancing (as indicated by decreases in population mobility) coincided with increases in infection-detection rate. Note the Omicron BA.1 wave spread rapidly, peaked ~1 month following the initial introduction, and subsided within ~2 months; thus, the inverse association was the strongest during the first 4 weeks (vs. the first 8 weeks for the 1<sup>st</sup> pandemic wave).

Wave	First N weeks	Calendar period	Correlation (95% CI)	P-value
1 <sup>st</sup> wave	4	03/01/2020 - 04/04/2020	-0.8 (-1, 0.69)	0.2
	6	03/01/2020 - 04/18/2020	-0.82 (-0.98, -0.02)	0.046
	8	03/01/2020 - 05/02/2020	-0.81 (-0.96, -0.24)	0.015
Omicron BA.1 wave	4	11/21/2021 - 12/25/2021	-0.96 (-1, -0.05)	0.035
	6	11/21/2021 - 01/08/2022	-0.29 (-0.89, 0.68)	0.58
	8	11/21/2021 - 01/22/2022	-0.28 (-0.82, 0.53)	0.5

**Table S3.** Prior ranges for model parameters and variables.

Period	Parameter	Symbol	Age group	Range	Note
	Vaccine efficacy (VE)		All	Before Delta: VE1=85%, VE2 = 95%; Delta: VE1 = 35.6%, VE2 = 88%, VE3 = 90%; Omicron: VE1 = 35%, VE2 = 70%, VE3 = 70%, VE4 = 70%, VE5 (bivalent) = 90%	Based on VE against symptomatic disease
	VE waning	$\rho$	All	$\rho(t) = 1/(1+\exp(-k * (t - t_{m.imm}/2))$ ; for wildtype: $k = 0.026$ ; $t_{m.imm} = 322$ ; for Delta: $k = 0.025$ ; $t_{m.imm} = 280$ ; for Omicron: $k = 0.024$ ; $t_{m.imm} = 256$	Parameter in the logistic function fitted based on data from UKHSA (ref 63)
Pre-Omicron	Citywide transmission rate (per day)	$\beta_{city}$	<1 year	U [0.25, 0.5]	Uniform distribution, based on an overall transmission rate of 0.5–1 and adjusting for contact rate for the age group (same below)
Pre-Omicron	Citywide transmission rate (per day)	$\beta_{city}$	1-4 years	U [0.26, 0.52]	-
Pre-Omicron	Citywide transmission rate (per day)	$\beta_{city}$	5-14 years	U [0.33, 0.67]	-
Pre-Omicron	Citywide transmission rate (per day)	$\beta_{city}$	15-24 years	U [0.38, 0.77]	-
Pre-Omicron	Citywide transmission rate (per day)	$\beta_{city}$	25-44 years	U [0.69, 1.4]	-
Pre-Omicron	Citywide transmission rate (per day)	$\beta_{city}$	45-64 years	U [0.5, 1]	-



Pre-Omicron	Citywide transmission rate (per day)	$\beta_{city}$	65-74 years	U [0.25, 0.5]	-
Pre-Omicron	Citywide transmission rate (per day)	$\beta_{city}$	75+ years	U [0.25, 0.5]	-
Pre-Omicron	Latency period (days)	Z	All	U [2, 5]	-
Pre-Omicron	Infectious period (days)	D	All	U [2, 5]	-
Pre-Omicron	Immunity period (days)	L	<1 year	U [180, 550]	-
Pre-Omicron	Immunity period (days)	L	1-4 years	U [910, 1300]	-
Pre-Omicron	Immunity period (days)	L	5-14 years	U [910, 1300]	-
Pre-Omicron	Immunity period (days)	L	15-24 years	U [910, 1300]	-
Pre-Omicron	Immunity period (days)	L	25-44 years	U [910, 1300]	-
Pre-Omicron	Immunity period (days)	L	45-64 years	U [910, 1300]	-
Pre-Omicron	Immunity period (days)	L	65-74 years	U [910, 1300]	-
Pre-Omicron	Immunity period (days)	L	75+ years	U [910, 1300]	-
Pre-Omicron	Time-to-detection, mean (days)	Td, mean	All	U [3, 8]	-
Pre-Omicron	Time-to-detection, SD (days)	Td,sd	All	U [1, 3]	-
Pre-Omicron	Infection-detection rate	IDR	<1 years	U [0.001, 0.05]	-

Pre-Omicron	Infection-detection rate	IDR	1-4 years	U [1e-04, 0.05]	-
Pre-Omicron	Infection-detection rate	IDR	5-14 years	U [1e-04, 0.05]	-
Pre-Omicron	Infection-detection rate	IDR	15-24 years	U [1e-04, 0.05]	-
Pre-Omicron	Infection-detection rate	IDR	25-44 years	U [0.001, 0.05]	-
Pre-Omicron	Infection-detection rate	IDR	45-64 years	U [0.001, 0.05]	-
Pre-Omicron	Infection-detection rate	IDR	65-74 years	U [0.001, 0.05]	-
Pre-Omicron	Infection-detection rate	IDR	75+ years	U [0.001, 0.05]	-
Pre-Omicron	Infection-fatality risk	IFR	<1 years	U [5e-05, 0.00015]	-
Pre-Omicron	Infection-fatality risk	IFR	1-4 years	U [5e-05, 0.00015]	-
Pre-Omicron	Infection-fatality risk	IFR	5-14 years	U [5e-05, 0.00015]	-
Pre-Omicron	Infection-fatality risk	IFR	15-24 years	U [5e-05, 0.00015]	-
Pre-Omicron	Infection-fatality risk	IFR	25-44 years	U [5e-04, 0.0015]	-
Pre-Omicron	Infection-fatality risk	IFR	45-64 years	U [0.005, 0.015]	-
Pre-Omicron	Infection-fatality risk	IFR	65-74 years	U [0.01, 0.1]	-
Pre-Omicron	Infection-fatality risk	IFR	75+ years	U [0.02, 0.2]	-
Pre-Omicron	Infection-to-ED ratio	EDR	<1 years	U [0.005, 0.1]	-

Pre-Omicron	Infection-to-ED ratio	EDR	1-4 years	U [0.005, 0.1]	-
Pre-Omicron	Infection-to-ED ratio	EDR	5-14 years	U [1e-04, 0.02]	-
Pre-Omicron	Infection-to-ED ratio	EDR	15-24 years	U [0.001, 0.03]	-
Pre-Omicron	Infection-to-ED ratio	EDR	25-44 years	U [0.001, 0.03]	-
Pre-Omicron	Infection-to-ED ratio	EDR	45-64 years	U [0.001, 0.06]	-
Pre-Omicron	Infection-to-ED ratio	EDR	65-74 years	U [0.01, 0.2]	-
Pre-Omicron	Infection-to-ED ratio	EDR	75+ years	U [0.01, 0.3]	-
Omicron	Citywide transmission rate (per day)	$\beta_{city}$	<1 years	U [0.61, 0.8]	-
Omicron	Citywide transmission rate (per day)	$\beta_{city}$	1-4 years	U [0.66, 0.85]	-
Omicron	Citywide transmission rate (per day)	$\beta_{city}$	5-14 years	U [0.91, 1.2]	-
Omicron	Citywide transmission rate (per day)	$\beta_{city}$	15-24 years	U [1, 1.3]	-
Omicron	Citywide transmission rate (per day)	$\beta_{city}$	25-44 years	U [1.6, 2.1]	-
Omicron	Citywide transmission rate (per day)	$\beta_{city}$	45-64 years	U [1.2, 1.6]	-

Omicron	Citywide transmission rate (per day)	$\beta_{city}$	65-74 years	U [0.6, 0.76]	-
Omicron	Citywide transmission rate (per day)	$\beta_{city}$	75+ years	U [0.58, 0.75]	-
Omicron	Latency period (days)	Z	<1 years	U [2.2, 3.8]	-
Omicron	Latency period (days)	Z	1-4 years	U [2.1, 3.6]	-
Omicron	Latency period (days)	Z	5-14 years	U [2, 3.5]	-
Omicron	Latency period (days)	Z	15-24 years	U [2.1, 3.6]	-
Omicron	Latency period (days)	Z	25-44 years	U [2.3, 3.8]	-
Omicron	Latency period (days)	Z	45-64 years	U [2.2, 3.6]	-
Omicron	Latency period (days)	Z	65-74 years	U [2.2, 3.7]	-
Omicron	Latency period (days)	Z	75+ years	U [2.2, 3.7]	-
Omicron	Infectious period (days)	D	<1 years	U [2.2, 2.9]	-
Omicron	Infectious period (days)	D	1-4 years	U [2.7, 3.5]	-
Omicron	Infectious period (days)	D	5-14 years	U [2.9, 3.7]	-
Omicron	Infectious period (days)	D	15-24 years	U [3.5, 4.5]	-
Omicron	Infectious period (days)	D	25-44 years	U [3.2, 4.1]	-

Omicron	Infectious period (days)	D	45-64 years	U [3.3, 4.2]	-
Omicron	Infectious period (days)	D	65-74 years	U [2.5, 3.2]	-
Omicron	Infectious period (days)	D	75+ years	U [2.7, 3.5]	-
Omicron	Immunity period (days)	L	<1 years	U [360, 470]	-
Omicron	Immunity period (days)	L	1-4 years	U [360, 1000]	-
Omicron	Immunity period (days)	L	5-14 years	U [360, 1100]	-
Omicron	Immunity period (days)	L	15-24 years	U [360, 1000]	-
Omicron	Immunity period (days)	L	25-44 years	U [360, 850]	-
Omicron	Immunity period (days)	L	45-64 years	U [360, 1100]	-
Omicron	Immunity period (days)	L	65-74 years	U [360, 990]	-
Omicron	Immunity period (days)	L	75+ years	U [360, 960]	-
Omicron	Time-to-detection, mean (days)	Td, mean	<1 years	U [3.7, 5.2]	-
Omicron	Time-to-detection, mean (days)	Td, mean	1-4 years	U [3.7, 5]	-
Omicron	Time-to-detection, mean (days)	Td, mean	5-14 years	U [3.8, 4.9]	-
Omicron	Time-to-detection, mean (days)	Td, mean	15-24 years	U [3.3, 4.3]	-
Omicron	Time-to-detection, mean (days)	Td, mean	25-44 years	U [4, 4.9]	-

Omicron	Time-to-detection, mean (days)	Td, mean	45-64 years	U [3.9, 4.8]	-
Omicron	Time-to-detection, mean (days)	Td, mean	65-74 years	U [4.2, 5.2]	-
Omicron	Time-to-detection, mean (days)	Td, mean	75+ years	U [4, 4.8]	-
Omicron	Time-to-detection, SD (days)	Td,sd	<1 years	U [1.5, 2.1]	-
Omicron	Time-to-detection, SD (days)	Td,sd	1-4 years	U [1.6, 2.2]	-
Omicron	Time-to-detection, SD (days)	Td,sd	5-14 years	U [1.7, 2.3]	-
Omicron	Time-to-detection, SD (days)	Td,sd	15-24 years	U [1.6, 2.2]	-
Omicron	Time-to-detection, SD (days)	Td,sd	25-44 years	U [1.9, 2.5]	-
Omicron	Time-to-detection, SD (days)	Td,sd	45-64 years	U [2, 2.5]	-
Omicron	Time-to-detection, SD (days)	Td,sd	65-74 years	U [1.7, 2.2]	-
Omicron	Time-to-detection, SD (days)	Td,sd	75+ years	U [1.7, 2.1]	-
Omicron	Infection-detection rate	IDR	All	U [0.01, 0.05]	-
Omicron	Infection-fatality risk	IFR	<1 years	U [6.1e-06, 2.8e-05]	-
Omicron	Infection-fatality risk	IFR	1-4 years	U [6.2e-06, 2.8e-05]	-
Omicron	Infection-fatality risk	IFR	5-14 years	U [6.2e-06, 2.8e-05]	-
Omicron	Infection-fatality risk	IFR	15-24 years	U [6e-06, 2.7e-05]	-

Omicron	Infection-fatality risk	IFR	25-44 years	U [4.3e-05, 0.00024]	-
Omicron	Infection-fatality risk	IFR	45-64 years	U [0.00039, 0.0021]	-
Omicron	Infection-fatality risk	IFR	65-74 years	U [0.0015, 0.005]	-
Omicron	Infection-fatality risk	IFR	75+ years	U [0.0037, 0.014]	-
Omicron	Infection-to-ED ratio	EDR	<1 years	U [0.0035, 0.029]	-
Omicron	Infection-to-ED ratio	EDR	1-4 years	U [0.0019, 0.013]	-
Omicron	Infection-to-ED ratio	EDR	5-14 years	U [0.00061, 0.0047]	-
Omicron	Infection-to-ED ratio	EDR	15-24 years	U [0.001, 0.0083]	-
Omicron	Infection-to-ED ratio	EDR	25-44 years	U [0.00097, 0.0069]	-
Omicron	Infection-to-ED ratio	EDR	45-64 years	U [0.0028, 0.019]	-
Omicron	Infection-to-ED ratio	EDR	65-74 years	U [0.0024, 0.017]	-
Omicron	Infection-to-ED ratio	EDR	75+ years	U [0.006, 0.041]	-